- News Home
5 December 2013 11:26 am ,
Vol. 342 ,
An animal rights group known as the Nonhuman Rights Project filed lawsuits in three New York courts this week in an...
Researchers have been hot on the trail of the elusive Denisovans, a type of ancient human known only by their DNA and...
Thousands of scientists in the Russian Academy of Sciences (RAS) are about to lose their jobs as a result of the...
Dyslexia, a learning disability that hinders reading, hasn't been associated with deficits in vision, hearing, or...
Exotic, elusive, and dangerous, snakes have fascinated humankind for millennia. They can be hard to find, yet their...
Researchers have sequenced and analyzed the first two snake genomes, which represent two evolutionary extremes. The...
Snake venoms are remarkably complex mixtures that can stun or kill prey within minutes. But more and more researchers...
At age 30, Dutch biologist Freek Vonk has built up a respectable career as a snake scientist. But in his home country,...
- 5 December 2013 11:26 am , Vol. 342 , #6163
- About Us
Immunologist Takes Scalpel to Merck R&D
1 October 2013 3:00 pm
Immunologist Roger Perlmutter is shaking things up again at Merck. After eliminating a corps of managers in June, the newly anointed Merck R&D chief is now following through on the “major surgery” that he promised in an interview in The Wall Street Journal last month. The drug giant will cut 8500 more jobs as part of its ongoing overhaul. The layoffs, amounting to roughly 20% of the workforce, are intended to cut operating expenses by $2.5 billion by the end of 2015, the company announced today in a press release.
Merck CEO Kenneth Frazier explained today in The Wall Street Journal that the firm aims to rebound from recent failures and devote more resources to the company’s most promising efforts, including cancer immunotherapy and diabetes research.